BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

4SC AG (VSC.DU) Says Vidofludimus Trial Missed Primary Efficacy Endpoint In RA


6/10/2011 7:12:13 AM

PLANEGG-MARTINSRIED, Germany--(BUSINESS WIRE)--4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced topline results from its randomised, double-blind, placebo-controlled Phase IIb clinical trial COMPONENT in RA. The trial compared vidofludimus, an oral inhibitor of DHODH and pro-inflammatory cytokines (including IL-17A and IL-17F as well as INF-gamma), in rheumatoid arthritis patients on methotrexate background therapy versus methotrexate monotherapy over a treatment period of 13 weeks.

ACR20 response improvement of the 35 mg vidofludimus group compared to placebo was statistically significant (p<0.05) at week 2 (16.7% vs. 6.9%) and week 8 (46.7% vs. 31.9%), however, vidofludimus missed the primary endpoint of significantly improving ACR20 response at week 13 (50.0% vs. 44.8%). Time to ACR20 response was significantly (p<0.05) shorter in the vidofludimus group compared to placebo (median 56 days vs. 92 days). The patient group treated with vidofludimus also reported higher ACR50 and ACR70 response rates compared to placebo at week 13. *All patients were on stable doses of methotrexate throughout the trial

*Confirmatory analysis of the primary efficacy endpoint (ACR20) has been performed for all randomized and exposed patients with a minimum of efficacy data available, i.e., at least one post-baseline efficacy observation (full analysis set included 236 patients)

Overall, vidofludimus was safe and well tolerated. No obvious differences in the adverse event rate between the vidofludimus and placebo group were observed. In particular, there were no relevant increases of diarrhea, neutropenia, anemia, hypertension, cholesterol or liver enzyme levels. Only one serious adverse event was reported in the vidofludimus group which was judged as not being related to vidofludimus. No deaths occurred. These safety results are consistent with previous Phase IIa trial results in RA and inflammatory bowel disease (IBD) patients.

'Even though we did not reach the primary efficacy endpoint,' said Dr Ulrich Dauer, CEO of 4SC AG, 'it is important to note that vidofludimus demonstrated efficacy in certain secondary parameters and showed very good tolerability in RA patients. We will continue to evaluate the novel mechanism of action of vidofludimus and use this new data set as an opportunity to advance our partnering discussions. We will continue our efforts for this compound in IBD and potentially other autoimmune indications such as lupus and psoriasis. Our Phase IIa trial in IBD achieved an excellent response rate of 88.5% and met the primary endpoint, both in Crohn's disease and ulcerative colitis patients. We feel this indication addresses an area of high unmet medical need that continues to be commercially attractive to potential partners and warrants the further development of vidofludimus based on the promising trial results.'


Read at BioSpace.com
Read at RTT News

4SC AG
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES